source for most antibiotics on the market today, including the first-line and salvage TB regimens, including rifampin, streptomycin, amikacin and etc. A set of Microbial Natural Product Library (MNPL) containing secondary metabolites from a unique collection of actinomycetes and fungal strains from unor under-explored ecological niches in China has been constructed. A pilot screen for potential anti-TB compounds was conducted with a selection of 5,000 extracts samples from this MNPL, utilizing a GFP labeled M. bovis BCG based HTS model (Z’-factor 0.8, CV 90% inhibition against logarithmically growing BCG were further evaluated on M. tb H37Rv strains at Broad Institute, as a dilution series ranging from 1× to 1/128×. The results showed that 46 extracts demonstrated anti-H37Rv activity, with 8 showing activity at 1/16×, and 1 showing activity at 1/128×. The following large scale fermentation and bioactivity guided compound isolation work lead to the discovery of diversified class of anti-TB compounds, including actinomycins (MIC 1 4 ug/ml), quinomycins (MIC 0.5 ug/ml), nanaomycins (MIC 8 ug/ml), cyclopeptides (MIC 2 8 ug/ml), anthraquinones (MIC 4 8 ug/ml), oligomycins, part of which were new compounds (not listed).
Read full abstract